School of Medicine, University of Wollongong, Wollongong, NSW, Australia.
Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
J Hum Nutr Diet. 2019 Feb;32(1):53-62. doi: 10.1111/jhn.12582. Epub 2018 Jul 8.
Evidence has shown that anthocyanins, a subclass of polyphenol, are metabolised in the gut, modulate bacterial species and exert bioactive effects through this interaction.
A systematic literature review was undertaken to determine the level of current evidence for the association between anthocyanin intake and changes in gut microbiota populations. The studies included were also assessed for the different techniques used in microbiota determination. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, scientific databases, including Scopus, PubMed, ScienceDirect, Web of Science and MEDLINE, were searched up to June 2017. Details on population/sample, study design, intervention/control, dosage and method of microbiota determination were extracted.
Six studies (three in vitro, two animal and one human trials) were included in the review, which showed that anthocyanins induced a significant proliferative effect on Bifidobacterium spp., known for their wide use in probiotics and for the treatment of irritable bowel syndrome. There was also an observed inhibition of Clostridium histolyticum, which was shown to be pathogenic in humans. The depth of analysis is an important consideration for the choice of microbiota determination technique with respect to a comprehensive, high-resolution microbiota analysis or analysis of the main microbiota taxa.
Very limited research has been carried out in the area of anthocyanins and gut microbiota; beneficial effects have generally been observed, and further clinical trials in humans are needed to confirm changes to gut microbes in relation to dietary anthocyanin intake and potential health benefits.
有证据表明,花色苷是多酚的一个子类,在肠道中代谢,通过这种相互作用调节细菌种类并发挥生物活性作用。
系统地进行了文献综述,以确定花色苷摄入量与肠道微生物群变化之间关联的现有证据水平。还评估了这些研究在微生物组确定方面使用的不同技术。根据 PRISMA(系统评价和荟萃分析的首选报告项目)指南,搜索了包括 Scopus、PubMed、ScienceDirect、Web of Science 和 MEDLINE 在内的科学数据库,截至 2017 年 6 月。提取了有关人群/样本、研究设计、干预/对照、剂量和微生物组确定方法的详细信息。
综述共纳入了 6 项研究(3 项体外研究、2 项动物研究和 1 项人体试验),这些研究表明花色苷对双歧杆菌属有显著的增殖作用,双歧杆菌属因其广泛用于益生菌和治疗肠易激综合征而闻名。同时也观察到对梭状芽胞杆菌属的抑制作用,梭状芽胞杆菌属在人类中被证明是致病的。分析的深度是选择微生物组确定技术的一个重要考虑因素,因为它涉及全面、高分辨率的微生物组分析或主要微生物群分类的分析。
花色苷与肠道微生物群的研究非常有限;一般观察到有益的效果,需要进一步的人体临床试验来证实与饮食花色苷摄入相关的肠道微生物群的变化以及潜在的健康益处。